

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target date to recruit patients agreed	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
11/NW/0075	67714	Lung ART: Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement	Number Agreed	4	4	Date Agreed	25/10/2018	2	18/05/2018	2	Recruitment Finished	Rare patient group
16/NE/0316	207651	CYP-01: An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease	Number Agreed	2	2	Date Agreed	29/09/2018	3	23/05/2018	3	Recruitment Finished	Target exceeded
17/ES/0032	212775	DSP-DE-MS-14-009: Global Liquid biopsy study in NSCLC	Number Agreed	1	30	Date Agreed	01/10/2018	19	03/07/2018	19	Recruitment Finished	Study recruitment target extended at Sponsor request, then Sponsor closed the study early.
10/H0706/65	5406	ARISTOTLE: A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer	Number Agreed	5	5	Date Agreed	29/06/2018	5	05/07/2018	5	Recruitment Finished	Target achieved
16/LO/1222	191705	ATLANTIS: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One	Number Agreed	6	6	Date Agreed	30/07/2018	6	30/07/2018	6	Recruitment Finished	Target achieved
13/NW/0134	105317	NEOBLADE: Phase II randomised placebo controlled Neoadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive bladder cancer	Number Agreed	12	12	Date Agreed	28/02/2018	35	11/09/2018	35	Recruitment Finished	Target exceeded
17/EE/0177	220722	BOSTON: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVD) versus bortezomib and dexamethasone (VD) in patients with Relapsed or Refractory Multiple Myeloma (RRMM)	Number Agreed	3	3	Date Agreed	01/12/2018	0	27/09/2018	0	Recruitment Finished	Rare Patient Group & study closed to recruitment earlier than expected, now re-opened to recruitment